Diabetes drug dapagliflozin could also be beneficial for patients with progressive liver disease, a clinical trial has shown.

For patients with MASH, treatment with dapagliflozin is beneficial for improvement of MASH without worsening of fibrosis and for improvement of fibrosis without worsening of MASH.

A new study found that dapagliflozin, a sodium glucose cotransporter 2 (SGLT-2) inhibitor, improved key liver conditions ...

New guidelines for treating heart failure could save 3,000 lives and prevent 5,500 hospital admissions every year, according ...

Around 3,000 lives could be saved and 5,500 hospital admissions prevented each year by changes to how people are treated for ...

A drug commonly used to treat type 2 diabetes may also help improve a serious liver condition, according to a new clinical ...